U.S. Biotechnology Pipeline Analysis

Published by: Frost & Sullivan

Published: Jan. 22, 2004

Table of Contents

Abstract

The need to offer newer treatment therapies is critical with lifestyle-related maladies such as obesity, type-II diabetes, and cardiovascular disorders on the rise. An increasing number of people suffering from lethal diseases such as cancer, AIDS, and auto-immune disorders and an ageing U.S. baby boomer population also require medical attention. These unmet healthcare requirements act as a major driver for the development of biologics.

This research examines the ongoing efforts to develop new biologic therapies. It offers detailed analysis of five path-breaking technologies with products under advanced clinical trials: monoclonal antibodies, gene therapy, cancer vaccines, cellular therapy, and cytokines. The comprehensive coverage is likely to help pharmaceutical and biotech companies formulate strategies for growth.

Robust Pipeline of Biologics Drives Dynamic Growth in the Biotech Industry

More than 370 drugs are undergoing clinical trials according to a survey conducted by the Pharmaceutical Research and Manufacturers of America (PhRMA). "The new drugs can address a plethora of serious medical conditions such as AIDS, cancer, diabetes and related conditions, autoimmune, blood disorders, digestive disorders, and cardiovascular disorders among others," says the analyst of this research service.

Exciting developments are taking place in the technologies of angiogenesis inhibitors, antisense, cellular therapy, colony stimulating factor, gene therapy, growth factors, and human growth hormones. Other areas of therapy poised for growth are immune-based therapy, cytokines, monoclonal antibodies, and recombinant human proteins.

Impending Expiry of Drug Patents Prompts New Biologics Drug Development

By 2006, patents for many pharmaceutical and biologic products will expire and competition from generics would be imminent. There is likely to be a decrease in sales and profits, compelling large pharmaceutical and biotech companies to develop new products that can contribute to the revenue stream.

"The many new monoclonal antibodies and new technology drugs such as cancer vaccines and gene therapy, on the verge of approval, will provide the needed momentum to the biotech industry to counter this challenge in the coming years," concludes the analyst.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.